Marinomed Biotech Initiates Capital Increase with Subscription Rights

Korneuburg-based Marinomed Biotech AG announced a capital increase to address short-term financial requirements. The biotech firm aims to raise EUR 2 million by issuing up to 459,985 new shares. This initiative allows public shareholders to participate in the capital increase via subscription rights. An institutional investor has already committed to purchasing shares worth EUR 1 million, aiding the process.

The subscription offer is set to start on March 26, 2026, with a duration of at least two weeks. If any shares remain unsubscribed, a rump placement will be available to eligible investors. The need for this capital arises from delayed payments following the transfer of Marinomed's Carragelose business to Unither Pharmaceuticals, leaving a liquidity gap.

Preliminary figures for 2025 indicate revenue increased to €7.7 million, influenced by a €5 million payment related to the Carragelose business sale. The financial update reveals a more optimistic fiscal outlook with a projected profit margin in future years, contingent on the licensing of key products, Budesolv and Tacrosolv.